Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Aktis Oncology, Inc. (AKTS) Stock Price & Analysis

42 Followers

AKTS Stock Chart & Stats

$17.04-$0.41(-2.35%)
At close: 4:00 PM EST
$15$20$25Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$17.03 - $17.87
52-Week Range
$13.96 - $34.19
Previous Close
$17.45
Volume
N/A
Average Volume (3M)
365.83K
Market Cap
$970.56M
Enterprise Value
$1.28B
Total Cash (Recent Filing)
$517.32M
Total Debt (Recent Filing)
$11.24M
Price to Earnings (P/E)
―
Beta
2.23
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.47
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Pipeline Breadth

Having three U.S. trials underway across two solid-tumor targets gives Aktis multiple clinical development paths and reduces reliance on a single program. Continued dose escalation and backfill cohorts could generate a broader evidence base for the pipeline over the next several quarters.

Revenue Growth

The sharp revenue increase demonstrates that Aktis has begun generating substantially more revenue from a small base, while strong gross margin indicates attractive economics on reported activity. If growth continues, it could improve the company’s ability to support development investment over time.

Radiopharmaceutical Platform

The company’s stated strategy extends radiopharmaceutical development across additional targets, indications, and patient populations. This platform-oriented approach could create multiple opportunities from the same broader technology base and support a wider oncology pipeline if clinical progress continues.

Bears Say

Severe Unprofitability

Aktis remains far from breakeven, with losses vastly exceeding current revenue and deeply negative EBITDA. This level of operating deficit means future growth must first overcome substantial fixed development spending, making profitability dependent on successful clinical progress and eventual commercialization.

Heavy Cash Burn

The reversal from positive operating and free cash flow in 2024 to substantial cash burn in 2025 materially increases funding needs. Persistent development spending without internally generated cash can constrain strategic flexibility and make continued access to external capital important.

Negative Equity

A deeply negative and worsening equity position signals accumulated financial strain despite modest absolute debt. It weakens the balance-sheet cushion available to absorb setbacks and increases the risk that future financing could be dilutive or otherwise costly to existing shareholders.

Aktis Oncology, Inc. News

AKTS FAQ

What was Aktis Oncology, Inc.’s price range in the past 12 months?
Aktis Oncology, Inc. lowest stock price was $13.96 and its highest was $34.19 in the past 12 months.
What is Aktis Oncology, Inc.’s market cap?
Aktis Oncology, Inc.’s market cap is $970.56M.
When is Aktis Oncology, Inc.’s upcoming earnings report date?
Aktis Oncology, Inc.’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is today.
How were Aktis Oncology, Inc.’s earnings last quarter?
Aktis Oncology, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.438 earnings per share for the quarter, missing the consensus estimate of -$0.431 by -$0.007.
Is Aktis Oncology, Inc. overvalued?
According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued.
Does Aktis Oncology, Inc. pay dividends?
Aktis Oncology, Inc. does not currently pay dividends.
What is Aktis Oncology, Inc.’s EPS estimate?
Aktis Oncology, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Aktis Oncology, Inc. have?
Aktis Oncology, Inc. has 53,746,670 shares outstanding.
What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?
Aktis Oncology, Inc. reported an EPS of -$0.438 in its last earnings report, missing expectations of -$0.431. Following the earnings report the stock price went up 4.792%.
Which hedge fund is a major shareholder of Aktis Oncology, Inc.?
Hedge funds hold Aktis Oncology, Inc. shares: the largest hedge-fund position in Aktis Oncology, Inc. is 71,883,870 shares, and hedge funds decreased their holdings by 172.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology